MUVON Therapeutics announced that Dr Christine Günther, MD, PhD, has been appointed Chief Technology Officer (CTO), effective December 1, 2025, as the clinical-stage biotech advances its regenerative medicine platform for skeletal muscle tissue repair. The company said her addition will strengthen its leadership team and support the next phase of technology development. Dr Günther brings over 30 years of experience in cell and gene therapy development, clinical translation, manufacturing and regulatory affairs, combining scientific innovation with operational leadership in the biotech sector. Her professional background includes more than a decade as CEO and Medical Director of Munich-based apceth (now part…
Author: Michael
Telomir Pharmaceuticals said that its lead therap
Life Time has opened a new adults-only fitness an
Regenerative medicine firm says new capital give
FDA clears ENV-308 for Phase 1 as Enveda doses f
Funding accelerates clinical rollout of glycan b
From insulin to GLP-1s, peptide therapies harnes
Urolithin A may support healthier immune aging.
PeptiDream and Alnylam Pharmaceuticals announced
Alnylam Pharmaceuticals said it will invest about